Bevacizumab in non-small cell lung cancer: new indication. Too many adverse effects to justify its use.
The numerous adverse effects (especially life-threatening infections and bleeding) outweigh the at best only moderate efficacy.
D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D017277:Drug Approval; D005060:Europe; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D009362:Neoplasm Metastasis / Q000188:drug therapy; D018307:Neoplasms, Squamous Cell / Q000188:drug therapy; D017671:Platinum Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D017671:Platinum Compounds; D042461:Vascular Endothelial Growth Factor A